Referências
Principais artigos
Fakhouri F, Zuber J, Frémeaux-Bacchi V, et al. Haemolytic uraemic syndrome. Lancet. 2017 Aug 12;390(10095):681-96. Resumo
Banatvala N, Griffin PM, Greene KD, et al. The United States national prospective hemolytic uremic syndrome study: microbiologic, serologic, clinical and epidemiologic findings. J Infect Dis. 2001 Apr 1;183(7):1063-70. Resumo
Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005 Mar 19-25;365(9464):1073-86. Resumo
Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000 Jun 29;342(26):1930-6.Texto completo Resumo
McKee RS, Schnadower D, Tarr PI, et al; Pediatric Emergency Medicine Collaborative Research Committee and Pediatric Emergency Research Canada. Predicting hemolytic uremic syndrome and renal replacement therapy in Shiga toxin-producing Escherichia coli-infected children. Clin Infect Dis. 2020 Apr 10;70(8):1643-51.Texto completo Resumo
Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli O157:H7 and the hemolytic uremic syndrome. N Engl J Med. 1995 Aug 10;333(6):364-8. Resumo
Rathbone J, Kaltenthaler E, Richards A, et al. A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open. 2013 Nov 4;3(11):e003573.Texto completo Resumo
Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016 Jan;31(1):15-39. Resumo
Artigos de referência
1. Keir LS, Saleem MA. Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol. 2014 Oct;29(10):1895-902. Resumo
2. Cody EM, Dixon BP. Hemolytic uremic syndrome. Pediatr Clin North Am. 2019 Feb;66(1):235-46. Resumo
3. Yan K, Desai K, Gullapalli L, et al. Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review. Clin Epidemiol. 2020 Mar 12;12:295-305.Texto completo Resumo
4. Nester CM, Andreoli SP. Renal involvement in children with HUS. In: Avner E, Harmon W, et al. (eds). Pediatric nephrology. 7th ed. Berlin, Heidelberg: Springer-Verlag; 2016.
5. Fakhouri F, Zuber J, Frémeaux-Bacchi V, et al. Haemolytic uraemic syndrome. Lancet. 2017 Aug 12;390(10095):681-96. Resumo
6. Atkinson JP, Liszewski MK, Richards A, et al. Hemolytic uremic syndrome: an example of insufficient complement regulation on self-tissue. Ann NY Acad Sci. 2005 Nov;1056:144-52. Resumo
7. Banatvala N, Griffin PM, Greene KD, et al. The United States national prospective hemolytic uremic syndrome study: microbiologic, serologic, clinical and epidemiologic findings. J Infect Dis. 2001 Apr 1;183(7):1063-70. Resumo
8. Bell BP, Goldoft M, Griffin PM, et al. A multistate outbreak of Escherichia coli 0157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. JAMA. 1994 Nov 2;272(17):1349-53. Resumo
9. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005 Mar 19-25;365(9464):1073-86. Resumo
10. Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000 Jun 29;342(26):1930-6.Texto completo Resumo
11. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol. 2005 Apr;16(4):1035-50.Texto completo Resumo
12. Zimmerhackl LB, Besbas N, Jungraithmayr T, et al; European Study Group for Haemolytic Uraemic Syndromes and Related Disorders. Epidemiology, clinical presentation and pathophysiology of atypical and recurrent hemolytic uremic syndrome. Semin Thromb Hemost. 2006 Mar;32(2):113-20. Resumo
13. Adams N, Byrne L, Rose T, et al. Sociodemographic and clinical risk factors for paediatric typical haemolytic uraemic syndrome: retrospective cohort study. BMJ Paediatr Open. 2019 Dec 17;3(1):e000465.Texto completo Resumo
14. McKee RS, Schnadower D, Tarr PI, et al; Pediatric Emergency Medicine Collaborative Research Committee and Pediatric Emergency Research Canada. Predicting hemolytic uremic syndrome and renal replacement therapy in Shiga toxin-producing Escherichia coli-infected children. Clin Infect Dis. 2020 Apr 10;70(8):1643-51.Texto completo Resumo
15. Public Health England. Shiga toxin-producing Escherichia coli (STEC) data: 2019. Apr 2022 [internet publication].Texto completo
16. Cochran JB, Panzarino VM, Maes LY, et al. Pneumococcus-induced T-antigen activation in hemolytic uremic syndrome and anemia. Pediatr Nephrol. 2004 Mar;19(3):317-21. Resumo
17. Warwicker P, Goodship TH, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 1998 Apr;53(4):836-44. Resumo
18. Jokiranta TS. HUS and atypical HUS. Blood. 2017 May 25;129(21):2847-56.Texto completo Resumo
19. Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res. 2011 Sep 15;17(18):5858-66. Resumo
20. Mead PS, Griffin PM. Escherichia coli O157:H7. Lancet. 1998 Oct 10;352(9135):1207-12. Resumo
21. Centers for Disease Control and Prevention. Reports of selected E. coli outbreak investigations. Dec 2021 [internet publication].Texto completo
22. Tabuchi A, Wakui T, Yahata Y, et al. A large outbreak of enterohaemorrhagic Escherichia coli O157, caused by low-salt pickled Napa cabbage in nursing homes, Japan, 2012. Western Pac Surveill Response J. 2015 Apr-Jun;6(2):7-11.Texto completo Resumo
23. Wikswo ME, Hall AJ, Centers for Disease Control and Prevention. Outbreaks of acute gastroenteritis transmitted by person-to-person contact - United States, 2009-2010. MMWR Surveill Summ. 2012 Dec 14;61(9):1-12.Texto completo Resumo
24. Dixon BP, Gruppo RA. Atypical hemolytic uremic syndrome. Pediatr Clin North Am. 2018 Jun;65(3):509-25. Resumo
25. Seaby EG, Gilbert RD. Thrombotic microangiopathy following haematopoietic stem cell transplant. Pediatr Nephrol. 2018 Sep;33(9):1489-500.Texto completo Resumo
26. Al-Nouri ZL, Reese JA, Terrell DR, et al. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood. 2015 Jan 22;125(4):616-8.Texto completo Resumo
27. Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol. 2001 Sep;8(5):286-93. Resumo
28. Bruel A, Kavanagh D, Noris M, et al. Hemolytic uremic syndrome in pregnancy and postpartum. Clin J Am Soc Nephrol. 2017 Aug 7;12(8):1237-47.Texto completo Resumo
29. Fakhouri F, Scully M, Provôt F, et al. Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood. 2020 Nov 5;136(19):2103-17.Texto completo Resumo
30. Thomas DE, Elliott EJ. Interventions for preventing diarrhea-associated hemolytic uremic syndrome: systematic review. BMC Public Health. 2013 Sep 3;13:799.Texto completo Resumo
31. Karch H, Janetzki-Mittmann C, Aleksic S, et al. Isolation of enterohemorrhagic Escherichia coli O157 strain from patients with hemolytic uremic syndrome by using immunomagnetic separation, DNA based methods and direct culture. J Clin Microbiol. 1996 Mar;34(3):516-9. Resumo
32. Xie J, Tarr GAM, Ali S, et al. Pigment visibility on rectal swabs used to detect enteropathogens: a prospective cohort study. J Clin Microbiol. 2019 Jun;57(6):e00213-19.Texto completo Resumo
33. Lee H, Kang E, Kang HG, et al. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020 Jan;35(1):25-40.Texto completo Resumo
34. McCrae KR. Thrombocytopenia in pregnancy: differential diagnosis, pathogenesis and management. Blood Rev. 2003 Mar;17(1):7-14. Resumo
35. Slutsker L, Ries AA, Greene KD, et al. Escherichia coli O157:H7 diarrhea in the United States: clinical and epidemiologic features. Ann Intern Med. 1997 Apr 1;126(7):505-13. Resumo
36. Cataland SR, Wu HM. How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood. 2014 Apr 17;123(16):2478-84.Texto completo Resumo
37. Remuzzi G, Ruggenenti P. The hemolytic uremic syndrome. Kidney Int. 1995 Jul;48(1):2-19. Resumo
38. Gerber A, Karch H, Allerberger F, et al. Clinical course and the role of Shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J Infect Dis. 2002 Aug 15;186(4):493-500. Resumo
39. Baccini V, Geneviève F, Jacqmin H, et al. Platelet counting: ugly traps and good advice. Proposals from the French-speaking Cellular Hematology Group (GFHC). J Clin Med. 2020 Mar 16;9(3):808.Texto completo Resumo
40. Kavanagh D, Richards A, Fremeaux-Bacchi V, et al. Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2007 May;2(3):591-6. Resumo
41. Veyradier A, Obert B, Houllier A, et al. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood. 2001 Sep 15;98(6):1765-72. Resumo
42. Mannucci PM. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome: much progress and many remaining issues. Haematologica. 2007 Jul;92(7):878-80. Resumo
43. Sevitt LH, Naish P, Baker LR, et al. The significance of microangiopathic haemolytic anaemia in accelerated hypertension. Br J Haematol. 1973 Apr;24(4):503-10. Resumo
44. Musio F, Bohen EM, Yuan CM, et al. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum. 1998 Aug;28(1):1-19. Resumo
45. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients. Medicine (Baltimore). 1998 May;77(3):195-207. Resumo
46. Merrill JT, Asherson RA. Catastrophic antiphospholipid syndrome. Nat Clin Pract Rheumatol. 2006 Feb;2(2):81-9. Resumo
47. McCrae KR, Cines DB. Thrombotic microangiopathy during pregnancy. Semin Hematol. 1997 Apr;34(2):148-58. Resumo
48. Michael M, Elliott EJ, Ridley GF, et al. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD003595.Texto completo Resumo
49. Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli O157:H7 and the hemolytic uremic syndrome. N Engl J Med. 1995 Aug 10;333(6):364-8. Resumo
50. Hickey CA, Beattie TJ, Cowieson J, et al. Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med. 2011 Oct;165(10):884-9.Texto completo Resumo
51. Ardissino G, Tel F, Possenti I, et al. Early volume expansion and outcomes of hemolytic uremic syndrome. Pediatrics. 2016 Jan;137(1):e20152153. Resumo
52. Tarr PI, Neill MA. Escherichia coli O157:H7. Gastroenterol Clin North Am. 2001 Sep;30(3):735-51. Resumo
53. Siegler RL. The hemolytic uremic syndrome. Pediatr Clin North Am. 1995 Dec;42(6):1505-29. Resumo
54. Caletti MG, Lejarraga H, Kelmansky D, et al. Two different therapeutic regimes in patients with sequelae of hemolytic-uremic syndrome. Pediatr Nephrol. 2004 Oct;19(10):1148-52. Resumo
55. Van Dyck M, Proesmans W. Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome. Pediatr Nephrol. 2004 Jun;19(6):688-90. Resumo
56. Imdad A, Mackoff SP, Urciuoli DM, et al. Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome. Cochrane Database Syst Rev. 2021 Jul 5;(7):CD012997.Texto completo Resumo
57. Centers for Disease Control and Prevention. E. coli (Escherichia coli). Resources for clinicians and laboratories. Dec 2014 [internet publication].Texto completo
58. Wong CS, Mooney JC, Brandt JR, et al. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis. 2012 Jul;55(1):33-41.Texto completo Resumo
59. Nelson JM, Griffin PM, Jones TF, et al. Antimicrobial and antimotility agent use in persons with shiga toxin-producing Escherichia coli O157 infection in FoodNet Sites. Clin Infect Dis. 2011 May;52(9):1130-2.Texto completo Resumo
60. Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. Clin Infect Dis. 2017 Nov 29;65(12):e45-80.Texto completo Resumo
61. Cimolai N, Morrison BJ, Carter JE. Risk factors for the central nervous system manifestations of gastroenteritis-associated hemolytic-uremic syndrome. Pediatrics. 1992 Oct;90(4):616-21. Resumo
62. Bell WR, Braine HG, Ness PM, et al. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. N Engl J Med. 1991 Aug 8;325(6):398-403. Resumo
63. Siegler RL, Pavia AT, Christofferson RD. A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah. Pediatrics. 1994 Jul;94(1):35-40. Resumo
64. Rowe PC, Orrbine E, Lior H, et al. Risk of hemolytic uremic syndrome after sporadic Escherichia coli O157:H7 infection: results of a Canadian collaborative study. J Pediatr. 1998 May;132(5):777-82. Resumo
65. Upadhyaya K, Barwick K, Fishaut M, et al. The importance of nonrenal involvement in hemolytic-uremic syndrome. Pediatrics. 1980 Jan;65(1):115-20. Resumo
66. Grodinsky S, Telmesani A, Robson WL, et al. Gastrointestinal manifestations of hemolytic uremic syndrome: recognition of pancreatitis. J Pediatr Gastroenterol Nutr. 1990 Nov;11(4):518-24. Resumo
67. Rigamonti D, Simonetti GD. Direct cardiac involvement in childhood hemolytic-uremic syndrome: case report and review of the literature. Eur J Pediatr. 2016 Dec;175(12):1927-31. Resumo
68. Benvenuto F, Guillen S, Marchiscio L, et al. Purtscher-like retinopathy in a paediatric patient with haemolytic uraemic syndrome: a case report and literature review. Arch Soc Esp Oftalmol (Engl Ed). 2021 Nov;96(11):607-10. Resumo
69. Mauras M, Bacchetta J, Duncan A, et al. Escherichia coli-associated hemolytic uremic syndrome and severe chronic hepatocellular cholestasis: complication or side effect of eculizumab? Pediatr Nephrol. 2019 Jul;34(7):1289-93. Resumo
70. Rathbone J, Kaltenthaler E, Richards A, et al. A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open. 2013 Nov 4;3(11):e003573.Texto completo Resumo
71. Menne J, Delmas Y, Fakhouri F, et al. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol. 2019 Apr 10;20(1):125.Texto completo Resumo
72. Pugh D, O'Sullivan ED, Duthie FA, et al. Interventions for atypical haemolytic uraemic syndrome. Cochrane Database Syst Rev. 2021 Mar 23;(3):CD012862.Texto completo Resumo
73. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013 Jun 6;368(23):2169-81.Texto completo Resumo
74. Licht C, Greenbaum LA, Muus P, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015 May;87(5):1061-73.Texto completo Resumo
75. Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016 Jan;31(1):15-39. Resumo
76. Ferraris JR, Ramirez JA, Ruiz S, et al. Shiga toxin-associated hemolytic uremic syndrome: absence of recurrence after renal transplantation. Pediatr Nephrol. 2002 Oct;17(10):809-14. Resumo
77. Barbour T, Scully M, Ariceta G, et al; 311 Study Group Members. Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults. Kidney Int Rep. 2021 Jun;6(6):1603-13.Texto completo Resumo
78. Tanaka K, Adams B, Aris AM, et al. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Pediatr Nephrol. 2021 Apr;36(4):889-98.Texto completo Resumo
79. ClinicalTrials.gov. Study of ravulizumab in children and adolescents with atypical hemolytic uremic syndrome (aHUS). NCT03131219. Apr 2022 [internet publication].Texto completo
80. ClinicalTrials.gov. Study of ALXN1210 in complement inhibitor treatment-naïve adult and adolescent participants with atypical hemolytic uremic syndrome (aHUS). NCT02949128. Mar 2022 [internet publication].Texto completo
81. Mody RK, Gu W, Griffin PM, et al. Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death. J Pediatr. 2015 Apr;166(4):1022-9. Resumo
82. Sheth KJ, Swick HM, Haworth N. Neurological involvement in hemolytic-uremic syndrome. Ann Neurol. 1986 Jan;19(1):90-3. Resumo
83. Constantinescu AR, Bitzan M, Weiss LS, et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis. 2004 Jun;43(6):976-82. Resumo
84. Murgo A. Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents. Semin Hematol. 1987 Jul;24(3):161-77. Resumo
85. Fuge R, Bird JM, Fraser A, et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol. 2001 Apr;113(1):58-64. Resumo
86. Kwaan HC, Gordon LI. Thrombotic microangiopathy in the cancer patient. Acta Haemat. 2001;106(1-2):52-6. Resumo
87. Ohali M, Shalev H, Schlesinger M, et al. Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H. Pediatr Nephrol. 1998 Oct;12(8):619-24. Resumo
88. Rougier N, Kazatchkine MD, Rougier JP, et al. Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol. 1998 Dec;9(12):2318-26. Resumo
89. Landau D. Shalev J, Levy-Finer G, et al. Familial hemolytic uremic syndrome associated with complement factor H deficiency. J Pediatr. 2001 Mar;138(3):412-7. Resumo
90. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Kidney Int. 2001 Sep;60(3):831-46. Resumo
91. Brandt JR, Fouser LS, Watkins LS, et al. Escherichia coli O157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. J Pediatr. 1994 Oct;125(4):519-26. Resumo
92. Tapper D, Tarr P, Avner E, et al. Lessons learned in the management of hemolytic uremic syndrome in children. J Pediatr Surg. 1995 Feb;30(2):158-63. Resumo
93. Brandt JR, Joseph MW, Fouser LS, et al. Cholelithiasis following Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Nephrol. 1998 Apr;12(3):222-5. Resumo
94. Bozio CH, Isenhour C, McNamara LA. Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States. PLoS One. 2020;15(11):e0241989.Texto completo Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal